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Abstract
Background: The relationship between multidrug resistance (MDR), inappropriate empiric therapy (IET), and
mortality among patients with Acinetobacter baumannii (AB) remains unclear. We examined it using a large
U.S. database.
Methods: We conducted a retrospective cohort study using the Premier Research database (2009–2013) of 175 U.S.
hospitals. We included all adult patients admitted with pneumonia or sepsis as their principal diagnosis, or as a
secondary diagnosis in the setting of respiratory failure, along with antibiotic administration within 2 days of
admission. Only culture-confirmed infections were included. Resistance to at least three classes of antibiotics
defined multidrug-resistant AB (MDR-AB). We used logistic regression to compute the adjusted relative risk ratio
(RRR) of patients with MDR-AB receiving IET and IET’s impact on mortality.
Results: Among 1423 patients with AB infection, 1171 (82.3 %) had MDR-AB. Those with MDR-AB were older
(63.7 ± 15.4 vs. 61.0 ± 16.9 years, p = 0.014). Although chronic disease burden did not differ between groups, the
MDR-AB group had higher illness severity than those in the non-MDR-AB group (intensive care unit 68.0 % vs. 59.
5 %, p < 0.001; mechanical ventilation 56.2 % vs. 42.1 %, p < 0.001). Patients with MDR-AB were more likely to
receive IET than those in the non-MDR-AB group (76.2 % MDR-AB vs. 13.8 % non-MDR-AB, p < 0.001). In a regression
model, MDR-AB strongly predicted receipt of IET (adjusted RRR 5.5, 95 % CI 4.0–7.7, p < 0.001). IET exposure was
associated with higher hospital mortality (adjusted RRR 1.8, 95 % CI 1.4–2.3, p < 0.001).
Conclusions: In this large U.S. database, the prevalence of MDR-AB among patients with AB infection was > 80 %.
Harboring MDR-AB increased the risk of receiving IET more than fivefold, and IET nearly doubled hospital mortality.
Keywords: Pneumonia, Sepsis, Acinetobacter baumannii, Multidrug resistance, Inappropriate empiric therapy,
Outcomes
Background
The Centers for Disease Control and Prevention con-
siders Acinetobacter baumannii (AB) a “serious” threat
[1]. AB’s resistance mechanisms target both first-line
and salvage broad-spectrum agents, with approximate
doubling in carbapenem and multidrug resistance
(MDR) in the United States over the last decade [2, 3]. In
addition to its public health implications, the rising tide
of drug resistance presents a difficult clinical conundrum.
In serious infections, appropriate initial therapy deter-
mines clinical outcomes. However, more extensive drug
resistance makes it a challenge to select appropriate treat-
ment [4–13]. Carbapenem resistance among AB in severe
sepsis and/or septic shock increases the risk of receiving
inappropriate empiric therapy (IET) nearly threefold,
raising the risk of death [14]. Unfortunately, using car-
bapenems as empiric therapy in hopes of minimizing
IET drives increasing carbapenem resistance. Because
of the limited data on this issue in AB, we conducted
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a multicenter, retrospective cohort study to explore the
impact of MDR in IET and of IET on hospital mortality
in AB.
Methods
We conducted a multicenter retrospective cohort study
of patients admitted to the hospital with pneumonia
and/or sepsis and included in the Premier Research
database in the 2009–2013. We hypothesized that
multidrug-resistant AB (MDR-AB) (primary exposure)
increases the risk of receiving IET (primary outcome),
and that IET increases hospital mortality. Because this
study used already-existing, Health Insurance Portability
and Accountability Act (“HIPAA”)-compliant, fully de-
identified data, it was exempt from institutional review
board (IRB) review.
Patient population
Patients were included if they were adults (aged ≥ 18 years)
hospitalized with pneumonia and/or sepsis. Pneumonia
was identified by the principal diagnosis International
Classification of Diseases, Ninth Revision, Clinical Modifi-
cation (ICD-9-CM) codes 481–486, or by respiratory
failure codes (518.81 or 518.84) with pneumonia as a
secondary diagnosis. Sepsis was identified by the principal
diagnosis codes 038, 038.9, 020.0, 790.7, 995.92, or 785.52,
or by respiratory failure codes (518.81 or 518.84) with
sepsis as a secondary diagnosis [15–18]. Only patients
with community-onset (present on admission) infection
and antibiotic treatment beginning within the first 2
hospital days and continued for at least three consecutive
days or until discharge were included [15–17]. Patients
were excluded if they had been transferred from another
acute care facility, had cystic fibrosis, or had a hospital
length of stay of 1 day or less. Those with both pneu-
monia and sepsis were included in the pneumonia group.
Patients were followed until death in or discharge from
the hospital. Only patients with a positive AB culture
from a pulmonary or blood source who met the above
criteria were included in the analysis.
Data source
The Premier Research database, an electronic laboratory,
pharmacy, and billing data repository for 2009–2013,
contains approximately 15 % of all U.S. hospitalizations
nationwide. In addition to patient age, sex, race and/or
ethnicity, principal and secondary diagnoses, and proce-
dures, the database contains a date-stamped log of all
medications, laboratory tests, and diagnostic and thera-
peutic services charged to the patient or the patient’s
insurer. We used data from 176 U.S. institutions that
submit microbiological data into the database. Eligible
time began only following the commencement of micro-
biological data submission by each institution.
Baseline variables
We classified infection (pneumonia or sepsis) as
healthcare-associated (HCA) if one or more of the follow-
ing were present: (1) prior hospitalization within 90 days of
the index hospitalization, (2) hemodialysis, (3) admission
from a long-term care facility, and/or (4) immune suppres-
sion. All other infections were considered community-
acquired (CA). Patient-level factors included demographic
variables and comorbid conditions. Charlson comorbidity
index score was computed as a measure of the burden of
chronic illness, while intensive care unit (ICU) admission,
mechanical ventilation, and vasopressor use served as
markers for disease severity. Hospital-level characteristics
examined were geographic region, size, teaching status, and
urbanicity.
Microbiological and treatment-related variables
and definitions
Blood and respiratory cultures had to be obtained within
the first 2 days of hospitalization. AB isolates were clas-
sified as S (susceptible), I (intermediate), or R (resistant).
For the purposes of the present analyses, I and R were
grouped together as nonsusceptible. MDR-AB was de-
fined, per Magiorakos et al., as any AB resistant to at
least one agent in at least three antimicrobial classes
[19]. Similarly, extensively drug resistant AB (XDR-AB)
was defined as an AB resistant to at least one agent in
all but two or fewer classes listed above, and pandrug-
resistant AB (PDR-AB) as an AB resistant to all anti-
microbial agents listed above [19].
IET was present if the antibiotic administered did not
cover the organism or if coverage did not start within
2 days of obtaining the positive culture. Because the role
of combination therapy in treating AB is not well defined,
combination therapy was not included in the definition
of IET [20]. IET was deemed “indeterminate” if the
susceptibility of AB to the regimen received was not
reported. These cases were excluded from the IET
analysis. All microbiological testing was performed at the
institutions contributing data to the database and con-
formed to the Clinical & Laboratory Standards Institute
standards.
Statistical analyses
We compared characteristics of patients infected with
MDR-AB with those of patients with non-MDR-AB
infection, as well as characteristics of patients who
received IET with those of patients treated with non-IET.
Continuous variables were reported as means with SD
when distributed normally or as medians with 25th and
75th percentiles when skewed. Differences between mean
values were tested via Student’s t test, and differences
between medians were assessed using the Mann-Whitney
U test. Categorical data were summarized as proportions,
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Table 1 Baseline characteristics
Non-MDR-AB (n = 252) % MDR-AB (n = 1171) % p Value
Mean age, years (SD) 61.0 (16.9) 63.7 (15.4) 0.014
Male sex 134 53.2 % 633 54.1 % 0.799
Race/ethnicity
White 134 53.2 % 633 54.1 % < 0.001
Black
Hispanic 159 63.1 % 738 63.0 %
Other 55 21.8 % 276 23.6 %
Admission source
Non-healthcare facility (including from home) 167 66.3 % 573 48.9 % < 0.001
Clinic 14 5.6 % 26 2.2 %
Transfer from ECF 13 5.2 % 280 23.9 %
Transfer from another non-acute care facility 3 1.2 % 45 3.8 %
Emergency department 54 21.4 % 236 20.2 %
Other 1 0.4 % 11 1.0 %
Elixhauser comorbidities
Congestive heart failure 61 24.2 % 353 30.1 % 0.060
Valvular disease 21 8.3 % 92 7.9 % 0.800
Pulmonary circulation disease 16 6.3 % 107 9.1 % 0.153
Peripheral vascular disease 33 13.1 % 145 12.4 % 0.756
Paralysis 32 12.7 % 292 24.9 % <0.001
Other neurological disorders 44 17.5 % 300 25.6 % 0.006
Chronic pulmonary disease 108 42.9 % 507 43.3 % 0.898
Diabetes without chronic complications 65 25.8 % 390 33.3 % 0.020
Diabetes with chronic complications 21 8.3 % 96 8.2 % 0.943
Hypothyroidism 28 11.1 % 182 15.5 % 0.072
Renal failure 66 26.2 % 359 30.7 % 0.160
Liver disease 17 6.7 % 37 3.2 % 0.007
Peptic ulcer disease with bleeding 0 0.0 % 0 0.0 % 1.000
AIDS 0 0.0 % 0 0.0 % 1.000
Lymphoma 1 0.4 % 16 1.4 % 0.336
Metastatic cancer 20 7.9 % 30 2.6 % < 0.001
Solid tumor without metastasis 17 6.7 % 31 2.6 % 0.001
Rheumatoid arthritis/collagen vascular 5 2.0 % 46 3.9 % 0.132
Coagulopathy 45 17.9 % 134 11.4 % 0.005
Obesity 41 16.3 % 191 16.3 % 0.987
Weight loss 49 19.4 % 392 33.5 % < 0.001
Fluid and electrolyte disorders 145 57.5 % 628 53.6 % 0.258
Chronic blood loss anemia 5 2.0 % 16 1.4 % 0.461
Deficiency anemia 97 38.5 % 593 50.6 % < 0.001
Alcohol abuse 22 8.7 % 35 3.0 % < 0.001
Drug abuse 16 6.3 % 29 2.5 % 0.001
Psychosis 13 5.2 % 77 6.6 % 0.402
Depression 29 11.5 % 161 13.7 % 0.343
Hypertension 158 62.7 % 669 57.1 % 0.104
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and chi-square test or Fisher’s exact test (when cell counts
were ≤4) was used to examine differences between groups.
We developed a generalized logistic regression model
to explore the relationship between MDR-AB and the
risk of IET. Covariates in the model included demo-
graphics (sex, age, whether the infection was HCA),
Elixhauser comorbidities, and measures of illness seve-
rity by hospital day 2. We calculated the relative risk
ratio with 95 % CI of receiving IET for MDR-AB vs.
non-MDR-AB, based on Huber-White robust standard
errors clustered at the hospital level [21]. To confirm
our results, we created two other models: (1) a nonparse
model that included all of the predictors in the genera-
lized logistic regression model with a large number of
additional treatments present or absent by hospital day
2, and (2) a propensity-matched model with propensity
for MDR-AB derived from a logistic regression model
using the nonparse model’s predictors, and MDR-AB
matched to non-MDR-AB patients using a 5:1 Greedy
algorithm [22, 23].
All tests were two-tailed, and a p value < 0.05 was
deemed a priori to represent statistical significance. All
analyses were performed in Stata/MP 13.1 for Windows
software (StataCorp LP, College Station, TX, USA).
Results
Among the 229,028 enrolled patients with pneumonia or
sepsis, 1423 (0.6 %) had a pulmonary or blood culture
positive for AB, of which 1171 (82.3 %) were MDR, 239
(16.8 %) were XDR, and 0 (0.0 %) were PDR. Patients
with MDR-AB were older (63.7 ± 15.4 vs. 61.0 ± 16.9 years,
p = 0.014) than those with non-MDR-AB, while the racial
distributions were comparable in both groups (Table 1).
Although the distribution of some chronic conditions
varied, there was no difference between the groups in the
Charlson comorbidity index (Table 1). MDR-AB was
more common than non-MDR-AB in the West and the
Midwest, in urban hospitals, and in hospitals of medium
size (200–499 beds). Both large hospitals (500+ beds) and
those with an academic program were less likely to have
MDR-AB than non-MDR-AB (Table 1).
In both groups (MDR-AB and non-MDR-AB), the
majority (approximately three-fourths) of the patients
had a diagnosis of sepsis, with the remaining one-fourth
having pneumonia (Table 2). Patients harboring MDR-AB
were more likely to have an HCA infection (64.9 % vs.
42.5 %, p < 0.001) along with higher illness severity by day
2 of admission (ICU 68.0 % vs. 59.5 %, p < 0.001; mecha-
nical ventilation 56.2 % vs. 42.1 %, p < 0.001; vasopressors
Table 1 Baseline characteristics (Continued)
Charlson comorbidity index score
0 58 23.0 % 247 21.1 % 0.542
1 60 23.8 % 298 25.4 %
2 50 19.8 % 244 20.8 %
3 35 13.9 % 179 15.3 %
4 21 8.3 % 112 9.6 %
5+ 28 11.1 % 91 7.8 %
Mean (SD) 2.2 (2.4) 2.0 (1.9) 0.096
Median [IQR] 2 [1–3] 2 [1–3] 0.873
Hospital characteristics
U.S. census region
Midwest 49 19.4 % 377 32.2 % < 0.001
Northeast 54 21.4 % 164 14.0 %
South 122 48.4 % 436 37.2 %
West 27 10.7 % 194 16.6 %
Number of beds
< 200 26 10.3 % 140 12.0 % 0.007
200–299 49 19.4 % 272 23.2 %
300–499 84 33.3 % 454 38.8 %
500+ 93 36.9 % 305 26.0 %
Teaching 137 54.4 % 537 45.9 % 0.014
Urban 233 92.5 % 1135 96.9 % 0.001
MDR-AB multidrug-resistant Acinetobacter baumannii, ECF extended care facility
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15.5 % vs. 17.6 %, p = 0.420) than non-MDR-AB patients
(Table 2). Although patients in the MDR-AB group had a
higher prevalence of use of antipseudomonal carbape-
nems, aminoglycosides, and polymyxins than those in the
non-MDR-AB group, they were also far more likely to
receive IET (76.2 % MDR-AB vs. 13.8 % non-MDR-AB,
p < 0.001), regardless of infection type (Fig. 1). Unadjusted
hospital mortality among patients with MDR-AB was
nearly double that in those with non-MDR-AB (23.7 % vs.
12.7 %, p < 0.001).
When we compared the cohort of 1098 patients (77.2 %
of all AB patients) with valid, known antimicrobial treat-
ment data based on the receipt of IET, we found that only
379 (34.5 %) received appropriate therapy (Table 3). The
rate of sepsis upon admission did not significantly differ
between IET and non-IET patients (Table 3). Unadjusted
hospital mortality was higher in patients receiving IET
than non-IET (23.6 % vs. 16.6 %, p = 0.007) in all infection
types (Fig. 2).
In a regression model designed to explore the impact
of MDR on the risk of IET exposure, MDR-AB was the
single strongest predictor of receiving IET (adjusted
relative risk ratio 5.5, 95 % CI 4.0–7.7, p < 0.001)
(Table 4). The confirmatory analyses produced similar
risk ratios (Table 4).
In a nonparse generalized regression model adjusting
for all confounders (demographics, comorbidities, seve-
rity of illness measures, hospital characteristics), IET was
associated with an increased risk of in-hospital mortality
(adjusted relative risk ratio 1.76; 95 % CI 1.36–2.28,
p < 0.001 (Table 4). The parse model and propensity-
matched analysis produced similar risk ratios.
Table 2 Infection characteristics and treatment
Non-MDR-AB (n = 252) % MDR-AB (n = 1171) % p Value
Infection characteristics
Sepsis 184 73.0 % 875 74.7 % 0.573
Pneumonia 68 27.0 % 296 25.3 %
HCA 107 42.5 % 760 64.9 % < 0.001
Illness severity measures by day 2
ICU admission 150 59.5 % 796 68.0 % 0.010
Mechanical ventilation 106 42.1 % 658 56.2 % < 0.001
Vasopressors 39 15.5 % 206 17.6 % 0.420
Antibiotics administered by day 2
Antipseudomonal penicillins with β-lactamase inhibitor 140 55.6 % 588 50.2 % 0.124
Extended-spectrum cephalosporins 100 39.7 % 373 31.9 % 0.017
Antipseudomonal fluoroquinolones 96 38.1 % 489 41.8 % 0.284
Antipseudomonal carbapenems 37 14.7 % 350 29.9 % < 0.001
Aminoglycosides 25 9.9 % 204 17.4 % 0.003
Penicillins with β-lactamase inhibitors 4 1.6 % 19 1.6 % 1.000
Tetracyclines 3 1.2 % 6 0.5 % 0.203
Folate pathway inhibitors 3 1.2 % 11 0.9 % 0.724
Polymyxins 0 0.0 % 37 3.2 % 0.001
Empiric treatment appropriateness
Non-IET 162 64.3 % 217 18.5 % < 0.001
IET 26 10.3 % 693 59.2 %
Indeterminate 64 25.4 % 261 22.3 %
Abbreviations: MDR-AB multidrug-resistant Acinetobacter baumannii, HCA healthcare-associated, ICU intensive care unit, IET inappropriate empiric therapy
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Fig. 1 Inappropriate empiric therapy as a function of multidrug
resistance (MDR). HCA healthcare-associated
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Table 3 Characteristics of the cohort, based on receipt of inappropriate empiric therapy
Non-IET (n = 379) % IET (n = 719) % p Value
Baseline characteristics
Mean age, years (SD) 62.4 (15.6) 62.7 (15.9) 0.767
Male sex 202 53.3 % 373 51.9 % 0.654
Race/ethnicity
White 236 62.3 % 464 64.5 % 0.055
Black 103 27.2 % 159 22.1 %
Hispanic 7 1.8 % 32 4.5 %
Other 33 8.7 % 64 8.9 %
Admission source
Non-healthcare facility (including from home) 223 58.8 % 357 49.7 % 0.022
Clinic 14 3.7 % 15 2.1 %
Transfer from ECF 69 18.2 % 173 24.1 %
Transfer from another non-acute care facility 8 2.1 % 20 2.8 %
Emergency department 63 16.6 % 148 20.6 %
Other 2 0.5 % 6 0.9 %
Elixhauser comorbidities
Congestive heart failure 97 21.5 % 209 30.4 % 0.222
Valvular disease 30 6.6 % 53 7.7 % 0.746
Pulmonary circulation disease 26 5.8 % 62 9.0 % 0.306
Peripheral vascular disease 51 11.3 % 82 11.9 % 0.322
Paralysis 85 18.8 % 176 25.6 % 0.448
Other neurological disorders 82 18.1 % 185 26.9 % 0.133
Chronic pulmonary disease 164 36.3 % 305 44.4 % 0.786
Diabetes without chronic complications 105 23.2 % 241 35.1 % 0.049
Diabetes with chronic complications 38 8.4 % 56 8.2 % 0.208
Hypothyroidism 49 10.8 % 119 17.3 % 0.113
Renal failure 107 23.7 % 217 31.6 % 0.501
Liver disease 17 3.8 % 27 3.9 % 0.557
Peptic ulcer disease with bleeding 0 0.0 % 0 0.0 % 1.000
AIDS 0 0.0 % 0 0.0 % 1.000
Lymphoma 2 0.4 % 10 1.5 % 0.236
Metastatic cancer 24 5.3 % 17 2.5 % 0.001
Solid tumor without metastasis 18 4.0 % 19 2.8 % 0.066
Rheumatoid arthritis/collagen vascular 11 2.4 % 29 4.2 % 0.342
Coagulopathy 58 12.8 % 83 12.1 % 0.077
Obesity 48 10.6 % 128 18.6 % 0.027
Weight loss 94 20.8 % 250 36.4 % 0.001
Fluid and electrolyte disorders 219 48.5 % 393 57.2 % 0.322
Chronic blood loss anemia 5 1.1 % 9 1.3 % 0.924
Deficiency anemia 173 38.3 % 363 52.8 % 0.127
Alcohol abuse 18 4.0 % 24 3.5 % 0.246
Drug abuse 16 3.5 % 19 2.8 % 0.157
Psychosis 22 4.9 % 45 6.6 % 0.765
Depression 50 11.1 % 96 14.0 % 0.941
Hypertension 215 47.6 % 413 60.1 % 0.821
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Table 3 Characteristics of the cohort, based on receipt of inappropriate empiric therapy (Continued)
Charlson comorbidity score
0 72 19.0 % 164 22.8 % 0.152
1 108 28.5 % 177 24.6 %
2 64 16.9 % 151 21.0 %
3 62 16.4 % 108 15.0 %
4 34 9.0 % 66 9.2 %
5+ 39 10.3 % 53 7.4 %
Mean (SD) 2.2 (2.2) 2.0 (1.9) 0.043
Median [IQR] 2 [1–3] 2 [1–3] 0.202
Infection characteristics and treatments
Infection characteristics
Sepsis 296 78.1 % 525 73.0 % 0.065
Pneumonia 83 21.9 % 194 27.0 %
HCA 222 58.6 % 464 64.5 % 0.053
MDR-AB 217 57.3 % 693 96.4 % < 0.001
Illness severity
ICU admission 249 65.7 % 482 67.0 % 0.655
Mechanical ventilation 206 54.4 % 390 54.2 % 0.972
Vasopressors 64 16.9 % 121 16.8 % 0.981
Antibiotics administered
Antipseudomonal penicillins with β-lactamase inhibitor 91 24.0 % 123 17.1 % 0.006
Antipseudomonal fluoroquinolones 97 25.6 % 209 29.1 % 0.222
Extended-spectrum cephalosporins 177 46.7 % 339 47.1 % 0.888
Antipseudomonal carbapenems 190 50.1 % 350 48.7 % 0.647
Aminoglycosides 140 36.9 % 269 37.4 % 0.877
Penicillins with β-lactamase inhibitors 5 1.3 % 9 1.3 % 0.924
Polymyxins 12 3.2 % 9 1.3 % 0.028
Folate pathway inhibitors 7 1.8 % 23 3.2 % 0.191
Tetracyclines 1 0.3 % 4 0.6 % 0.665
Hospital characteristics
U.S. region
Midwest 118 31.1 % 234 32.5 % < 0.001
Northeast 60 15.8 % 91 12.7 %
South 167 44.1 % 254 35.3 %
West 34 9.0 % 140 19.5 %
Number of beds
< 200 41 10.8 % 78 10.8 % 0.011
200–299 65 17.2 % 165 22.9 %
300–499 143 37.7 % 292 40.6 %
500+ 130 34.3 % 184 25.6 %
Teaching 212 55.9 % 292 40.6 % < 0.001
Urban 357 94.2 % 696 96.8 % 0.038
Hospital mortality 63 16.6 % 170 23.6 % 0.007
Abbreviations: IET inappropriate empiric therapy, ECF extended care facility, HCA healthcare-associated, MDR-AB multidrug-resistant Acinetobacter baumannii,
ICU intensive care unit
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Discussion
In this large, multicenter cohort study, we have demon-
strated that CA and HCA pneumonia and sepsis are
rarely caused by AB. However, when AB is present, it is
most often MDR. Moreover, harboring MDR puts pa-
tients at a fivefold increased risk of receiving IET, which
is in turn associated with increased hospital mortality.
Multiple investigators have documented the excee-
dingly high and rising rate of AB resistance. In a multi-
center microbiology database study in the United States,
we noted a rise in MDR-AB from 21.4 % between 2003
and 2005 to 35.2 % in the 2009–2012 period [3].
Similarly, the Center for Disease Dynamics, Economics
& Policy (CDDEP) reported an MDR-AB increase from
32.1 % in 2009 to 51.0 % in 2010 [2]. The discrepancy
between the two studies reflects the populations evalu-
ated and the definitions of MDR applied. While our
prior investigation was limited to only patients with
severe sepsis and septic shock, the CDDEP surveillance
included all infection sources. Additionally, we limited
drug definitions to those where clinical efficacy data
were available, while CDDEP included all pertinent drug
categories.
Our present study, though not longitudinal, confirms
the high probability of MDR-AB, though the rate is
higher than that in either of the surveillance studies.
Although the our examined population is more similar
to that in our previous surveillance study than to the
CDDEP surveillance, the IET definition is more in line
with that of the CDDEP [19]. Because our data represent
years 2009–2013, the high prevalence may simply be
consistent with continued growth of this resistant patho-
gen beyond the time frame examined in either of the
previous surveillance efforts.
We confirm that antimicrobial resistance confers a
high risk for IET. A previous single-center study reported
that having severe sepsis or septic shock caused by
carbapenem-resistant AB doubled the risk of IET [14].
This is the case for any gram-negative pathogen of severe
sepsis or septic shock [24]. In the present study, the effect
size was even greater, with a more than fivefold increase
in the relative risk of receiving IET compared with non-
MDR-AB. This suggests that clinicians should consider
broad empiric coverage when AB is either suspected or
identified by rapid testing.
In sepsis and pneumonia, it has been shown repeatedly
that IET increases hospital mortality two- to fourfold
and that escalation of treatment in response to culture
results fails to alter this outcome [4–13]. Specific to AB
sepsis and septic shock patients, Shorr et al. recently
reported a significantly elevated risk of mortality associated
with IET (risk ratio 1.42, 95 % CI 1.10–1.58, p = 0.015)
[14]. We confirm this observation in a cohort of patients
with AB pneumonia or sepsis. However, this association
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Fig. 2 Mortality and inappropriate empiric therapy.
HCA healthcare-associated
Table 4 Adjusted risk of inappropriate empiric therapy and hospital mortality
Risk of IET in the setting of MDR-AB Marginal effect, IET in
non-MDR-AB
Marginal effect,
IET in MDR-AB
Adjusted relative risk ratio
(95 % CI)
p Value
Method
Parse model 13.8 % 76.2 % 5.5 (4.0–7.7) < 0.001
Propensity score (based on 204 matched pairs;
81.0 % matched)
13.4 % 73.9 % 5.5 (3.6–8.4) < 0.001
Nonparse model 14.4 % 75.6 % 5.3 (3.7–7.4) < 0.001
Risk of death in the setting of IET Marginal effect, mortality
in non-IET
Marginal effect, mortality
in IET
Adjusted relative risk ratio
(95 % CI)
p Value
Method
Parse model 15.9 % 24.3 % 1.53 (1.21–1.93) < 0.001
Propensity score (based on 226 matched pairs;
59.6 % matched)
15.0 % 27.8 % 1.85 (1.35–2.54) < 0.001
Nonparse model 14.5 % 25.6 % 1.76 (1.36–2.28) < 0.001
IET inappropriate empiric therapy, MDR-AB multidrug-resistant Acinetobacter baumannii
Zilberberg et al. Critical Care  (2016) 20:221 Page 8 of 10
has not always been found in studies of AB infection.
While researchers in two additional cohort studies re-
ported a two- to sixfold rise in hospital mortality in asso-
ciation with IET for AB, six other study groups failed to
detect such an association [25–32]. Though it is not clear
why such a well-recognized relationship would not exist
specifically in the setting of AB, there are a number of
potential reasons for this divergence. Some of the previous
studies suffer from several methodological issues, such as
small sample size, incomplete adjustment for or unmea-
sured confounders, and overadjusting for some factors that
may be collinear.
Our study has a number of strengths and limitations.
It included a large multicenter cohort representative of
U.S. institutions and thus has broad generalizability.
Though largely representative of U.S. institutions overall,
the southern portion of the United States is overrepre-
sented in the database. Although this made the study
susceptible to bias, particularly selection bias, we dealt
with it by setting a priori enrollment criteria and defini-
tions for the main exposures and outcomes. Though
some misclassification is possible, the main exposures
(MDR-AB, IET) and outcomes (IET, hospital mortality)
are minimally susceptible to misclassification. At the
same time, in at least some of the identified cases, AB
might have represented colonization rather than true
infection. Additionally, the fact that fully one-third of all
MDR-AB were isolates from cases defined as CA suggests
that some misclassification may exist in this group; that is,
it is possible that we were unable to identify these patients’
exposure to the healthcare system with the variables
available in the current database. Although confounding is
a potential issue in observational studies, we attempted to
eliminate this through regression analyses using a large
number of potentially confounding variables. Neverthe-
less, the possibility of residual confounding remains.
Conclusions
In this largest representative multicenter study to date,
although AB was a rare pathogen in CA or HCA pneu-
monia or sepsis, over 80 % of the AB isolates exhibited
MDR. MDR increased the risk of receiving IET fivefold.
In turn, IET was associated with increased risk of in-
hospital mortality.
Key messages
 AB is a rare pathogen in community-acquired or
healthcare-associated pneumonia or sepsis.
 Eighty percent of all AB in this population is MDR.
 MDR raises the risk of receiving inappropriate
empiric therapy fivefold.
 Inappropriate empiric therapy increases the risk of
hospital mortality.
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